Peptide Chemical Synthesis
Aji Bio-Pharma Services manufactures peptide APIs by chemical synthesis using AJIPHASE™ — our proprietary liquid-phase synthesis platform. From short and medium-length sequences to longer peptides assembled by fragment condensation, and from standard linear sequences to cyclic, disulfide-constrained, PEGylated, or lipidated variants, our team designs and optimizes the right synthesis route from first material through GMP supply.
Chemical Synthesis Services
Custom Synthesis
Custom synthesis at gram to hundreds-of-grams scale to support preclinical studies, process development, and early-stage CMC activities — with high purity and rapid turnaround.
Process Development
Synthesis route design and optimization for short, long, and modified peptides — coupling efficiency, deprotection conditions, fragment strategy, and purification — to build a robust, scalable process before clinical manufacturing.
Analytical Characterization
In-house analytical method development covering purity by HPLC, identity by LC-MS, residual solvents, and endotoxin. Particular expertise in deletion sequence profiling and impurity identification for short peptides.
cGMP Manufacturing
Phase 1 and Phase 2 cGMP peptide manufacturing at our Tokai, Japan, Wetteren, Belgium, and Balen, Belgium sites — FDA, EMA, and PMDA inspected. CoA issued for every GMP batch.
CMC Support
Process development data packages and documentation to support IND CMC filings — process descriptions, analytical method summaries, and characterization data aligned with FDA and EMA expectations.
Technology Transfer
For programs moving to in-house manufacturing or a nominated partner CDMO: full technology transfer package including process descriptions, batch records, analytical method transfer, and on-site training.
Why AJIPHASE™ for Peptide Chemical Synthesis
AJIPHASE™ is our preferred route for most chemical synthesis programs — but we recommend the right synthesis strategy for each sequence. For very short sequences with unusual chemistry, our team will advise on the optimal approach.
Scale When You Need It
Programs that start on AJIPHASE™ stay on AJIPHASE™ through clinical supply. Same process, same team, same documentation — no CDMO handoff and no new CMC filing when you scale.
Lower Solvent and Reagent Consumption vs. SPPS
Even at small scale, AJIPHASE™ requires fewer equivalents of activating reagents and less solvent per cycle than solid-phase synthesis. Quantifiable improvement in PMI — confirmed via our EcoPass sustainability tool.
Broad Modification Support in a Single Platform
Cyclic peptides, disulfide-bridged structures, PEGylated variants, lipidated sequences, non-natural amino acids — the modifications that define modern peptide therapeutics are all supported within the same AJIPHASE™ workflow.
Standard Equipment — Straightforward Technology Transfer
AJIPHASE™ runs in standard chemical reactors — no proprietary synthesizer hardware required. For programs moving to in-house manufacturing or a nominated CDMO, the technology transfers cleanly.
Longer Sequences by Fragment Condensation
Fragment-based synthesis gives long-chain peptide programs a route forward — and a single partner from development through commercial supply.
Fragment-Based Synthesis
Long-chain peptides assembled via fragment condensation — individual segments synthesized separately, then ligated — extending AJIPHASE™ well beyond the continuous-chain ceiling.
Commercial-Scale Manufacturing
Same liquid-phase process from development through commercial supply. No platform switch required as programs scale — single process description, single regulatory filing.
Natural-Sequence Peptides at Large Volumes
For long peptides composed of natural amino acids and required at very large commercial volumes, CORYNEX™ recombinant expression offers an alternative manufacturing route.
Removing Barriers to Peptide Development
AJIPHASE™ is Ajinomoto Bio-Pharma Services’ proprietary liquid-phase peptide synthesis platform based on Tag-assisted chemistry. Unlike traditional solid-phase peptide synthesis, AJIPHASE™ performs synthesis in solution using standard chemical reactors, supporting efficient scale-up while reducing solvent and reagent consumption.
20+
Years peptide synthesis experience
0
Typical purity by HPLC
3
GMP sites in Belgium & Japan
Manufacturing Facilities
Three GMP-capable sites in Belgium and Japan providing geographic and regulatory redundancy for global programs.
Commercial API production
Wetteren, Belgium
Wetteren, Belgium — GMP manufacturing site. FDA and EMA inspected. Supports peptide programs requiring EU supply chain or EMA-compliant documentation.
Peptide synthesis
Balen, Belgium
Balen, Belgium — GMP peptide manufacturing capabilities, conventional liquid-phase synthesis, and flow chemistry technologies. Supports commercial production, scale-up, and long-term supply of peptide therapeutics.
AJIPHASE™ Production
Tokai, Japan
Tokai, Japan — primary AJIPHASE™ synthesis site. PMDA inspected. Full GMP capability from research-scale through commercial, with integrated process development, analytical, and manufacturing teams.
Tell Us About Your Peptide Synthesis Program.
Share your sequence, modifications, and scale requirements — our synthesis team will assess fit and recommend the right approach, typically within a few business days.
Frequently Asked Questions
What sequence lengths can AJIPHASE™ synthesize?
AJIPHASE™ supports short and medium-length peptides, typically from 2 to approximately 50 amino acids. For sequences beyond this range, ABPS uses fragment-based synthesis strategies via AJIPHASE™ or alternative routes — our team assesses the optimal approach based on your specific sequence, modifications, and scale requirements.
What peptide modifications does Aji Bio-Pharma support in chemical synthesis?
Aji Bio-Pharma supports a broad range of modifications for short and medium peptides via AJIPHASE™, including: cyclic peptides (head-to-tail and side-chain cyclization), disulfide-bridged structures, PEGylated and lipidated peptides, D-amino acid incorporation, non-natural amino acids, phosphopeptides, and fluorescent or biotin-labeled sequences. Confirm specific modifications not listed here with our team — the list above reflects standard capability, not the full scope of what we can support. Cyclic, disulfide-bridged (including multi-disulfide), and PEGylated peptides are handled within the same liquid-phase synthesis workflow; for lipidated peptides and other conjugates, Aji Bio-Pharma evaluates the optimal conjugation strategy for each sequence.
What is the turnaround time for research-grade peptide synthesis at Ajinomoto Bio-Pharma Services?
Typical research-grade turnaround depends on sequence length and modifications; our team provides a timeline estimate at program assessment.
What GMP regulatory frameworks does Aji Bio-Pharma support for synthetic peptide APIs?
Aji Bio-Pharma manufactures synthetic peptide APIs under GMP at three sites: Tokai, Japan (PMDA inspected; supports FDA and PMDA regulatory pathways), Wetteren, Belgium (FDA and EMA inspected; supports EU and US regulatory pathways), and Balen, Belgium (AJIPHASE™, conventional liquid-phase synthesis, and flow chemistry). All three sites are available for chemical synthesis programs — the optimal site is selected based on program scale, regulatory jurisdiction, and supply chain requirements.
How do I get started with a peptide synthesis program at Aji Bio-Pharma?
Share your sequence, key modifications, target scale, and regulatory stage with our team. We’ll assess fit, recommend the right synthesis route, and outline a development pathway. Most programs begin with a brief technical discussion — no lengthy RFI process required. Contact us using the form below to start the conversation.